To evaluate the Safety and Efficacy of ACELABS Serum

A Clinical Study to evaluate the Safety and Efficacy of ACELABS Lumiere Rebalancing Diamond Drop for advanced skin brightening. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2024/02/063322

Enrollment

Registered

2024-02-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product- Lumiere Rebalancing Diamond Drop: Dose: Apply 3 drops serum over the face with finger in outward manner. Duration- Two times a day Route of administration- Topical Control

Eligibility

Inclusion criteria

Inclusion criteria: 1.Gender: Male or Female aged between 20 to 30, with minimum F:M distribution ratio of 2:1 2.Subject willing to give written informed consent 3.Women of child bearing potential must have a negative urine pregnancy test 4.Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 5.Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1.Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2.Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 3.Have open sore or open lesions in the treatment area 4.Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 5.Have participated in any interventional clinical trial in the previous 30 days. 6.Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 7.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), blood purifiers and including corticosteroids. 8.Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

Measure	Time frame
change in skin brightening, lightening effects, hydration, with Spots monitoringTimepoint: Day 0 and Day 14	—

Secondary

Measure	Time frame
To assess the safety and tolerabilityTimepoint: 0-14 days	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org8937015757

Outcome results